TY  - CHAP
M1  - Book, Section
TI  - Chapter 92. Metastatic Breast Cancer
A1  - Rugo, Hope S.
A2  - Kuerer, Henry M.
PY  - 2010
T2  - Kuerer's Breast Surgical Oncology
AB  - Although  significant  advances  have  been  made  in  the  treatment  of  breast  cancer  resulting  in  continued  improvement  in  survival,  more  than  40,000  women  will  die  of  the  disease  this  year.1  Approximately  30%  of  women  diagnosed  with  early-stage  breast  cancer  will  develop  a  systemic  metastatic  recurrence,  with  only  a  few  of  these  patients  achieving  long-term  survival  with  standard  chemotherapy.2  In  addition,  5%  to  10%  of  women  are  diagnosed  with  metastatic  disease  at  first  presentation  of  breast  cancer.  Overall  survival  (OS)  for  patients  with  metastatic  disease  has  changed  little  over  the  last  50  years,  despite  a  marked  increase  in  the  choice  of  active  agents  for  treatment.  The  availability  of  new  targeted  biological  therapies,  particularly  trastuzumab  for  HER-2/neu  overexpressing  disease,  as  well  as  new  hormonal  and  chemotherapeutic  agents,  has  clearly  improved  outcome  for  patients  with  certain  biological  subtypes  of  this  disease.  However,  the  concept  of  treating  metastatic  breast  cancer  as  a  chronic  disease  is  still  largely  theoretical  because  most  patients  will  survive  less  than  5  years  following  diagnosis.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesssurgery.mhmedical.com/content.aspx?aid=6417687
ER  -